Objective: Local application of mitomycin-c (MMC) seems to be effective in reducing adhesions and stenosis after FESS. However this is not clearly seen in frontal sinusotomy. This study assesses the effectiveness of local MMC in the frontal ostium using a foamy material (otowick) and compared with cottonoids.
Introduction
Postoperative adhesions and ostium stenosis are common causes of functional endoscopic sinus surgery (FESS) failure (1, 2) . Granulation and scar tissue formation during the healing process can lead to persistent symptoms due to decreased sinus ventilation and mucus drainage. The complex anatomy of frontal recess makes the patency of frontal sinusotomy one of the most difficult aspects of FESS. Many studies showed that postoperative frontal ostium stenosis rated between 20-25% of patients (3) (4) (5) . The maintenance of a patent ostium is a significant factor for a successful operation and for this purpose many techniques have been developed, including local application of mitomycin-c (MMC).
MMC is an antibiotic-antineoplasmatic agent mainly used in chemotherapy of certain types of cancer. However, its local application in the nose has been shown to reduce scar formation via inhibition of fibroblasts proliferation (6) . Although increasing evidence exists regarding its positive effect on antrostomy patency after FESS, similar results were not clearly seen in the frontal sinus ostium (7) . This could be attributed to the use of neurosurgical cottonoids for local MMC application in the majority of studies (8, 9) . The above technique applies the drug in the surface of the operated middle meatus, however this presents certain limitations regarding the frontal sinus ostium. Owning to its shape, a deeper application of the drug is needed. The necessity for a material, which offers deeper and equal application of MMC in an "hourglass" shaped area, led our team to assess the efficacy of an otowick into the frontal ostium, in which MMC was injected.
Materials and methods

Patient population
In total 47 patients with chronic rhinosinusitis and bilateral frontal sinuses involvement enrolled in this sequential, cross-over study. Data were collected from the clinical notes of patients who failed maximal medical treatment and had undergone bilateral primary or revision FESS.
Patients with not an equal extent of the disease in both sides (difference in Lund -Mackay CT score > 2) and/or pathology like nasal allergic fungal sinusitis and nasal polyposis were excluded.
All patients provided written informed consent according to a protocol approved by the Ethic Committee of the Aristotle University and the Helsinki Declaration for human subjects. The ostium was considered as patent when suction could pass without any forceful movement, a fact which practically means that the ostium's size is ≥ 3mm (7) .
MMC treatment
At the end of the surgical procedure, 1ml of a 0.5mg/ml MMC solution was applied for 5 minutes in a randomized order onto the frontal ostium of one side and normal saline on the other side. Patients were divided in two groups with equal sex and age distribution. In the first study group, MMC application performed using soaked neurosurgical cottonoids and for the second group a 6 mm in length piece of an otowick (Merocel, Xomed Surgical Products Inc., Jacksonville, USA) was used ( Figure 1 ).
This size was chosen to cover the variability in frontal sinus ostium length (10) . The otowick was placed into the frontal ostium and then MMC was injected. When the MMC solution is injected into the otowick, it reshapes from cylindrical to hourglass covering equally all the area of surgical interest ( Figure 2 ). We did not use a cottonoid into the frontal ostium as its contact with an hourglass area cannot be standardized especially with the upper part. In both groups the same material was used in the control side as in the MMC side.
Then cottonoids and otowicks were removed and the nasal cavities were irrigated with sterile normal saline. All patients were discharged with a 10-days course of oral antibiotics, nasal steroids for 4 weeks and instructions for saline irrigation of the nose for up to 2 months.
Four weeks later, a second application of 1 ml of a 0.5mg/ml MMC solution was performed with the same technique after debridement of the nose at an outpatient setting (Figure 3) . Specifically, MMC was applied on the same side as in the operation using the same material (cottonoids or otowick). Final measurements performed at a 6 months postoperative follow-up assessment. At this appointment, a blinded observer regarding the MMC application side, performed nasal endoscopy with a 
Results
In total 25 men and 22 women were enrolled in this study (mean age, 51.7 years; range, 31-68 years).
Ostium patency
At a 6 months follow-up appointment, the overall patency rate was higher in the MMC side than in the control side (84.7% vs (n = number of patients). The asterisk symbolizes significant differences.
A comparison cannot be performed for revision surgery due to small sample size (ND = not determined). performed due to small sample size. Cottonoids did not present any significant effect in primary cases. All data of endoscopic findings are presented analytically in Table 1 . No difference between genders was found on the frontal ostium patency (p = 0.9). In addition no difference on the ostium patency was found between younger (< 45y.o) and older (≥ 45y.o.) patients (p = 0.77).
Need for revision surgery
Overall six patients (nine nasal cavities) needed an additional operation (12.75 % of patients). Among them six nasal cavities were control sides and three MMC sides (two cottonoid vs one otowick).
Two patients with primary surgery required further surgery (in the first patient the control side, in the second patient both the control and MMC cottonoid side).
In the revision cases, 2 patients with marked osseoneogenesis in the frontal ostium (1 in cottonoid subgroup/1 in otowick subgroup) required an additional operation in both frontal sinuses.
Moreover, 2 patients underwent further surgery in their control sides.
No complications or toxic effects were reported regarding the use of MMC in all follow-up assessments.
Discussion
Endoscopic surgery is the primary approach used today for the surgical treatment of chronic rhinosinusitis. However, frontal sinus ostium patency still present difficulties to maintain, and is one of the main causes for revision surgery (1, 2) . Different techniques and materials (balloon, mitomycin-c, stent) have been used for the prevention of frontal sinus ostium stenosis. Although the local application of MMC is supported by animal and experimental studies (11, 12) , its clinical value is still debatable especially for the frontal ostium (7, 8) . This is because clinical studies did not present convincing results (13) . In a recent review assessing all rhinological MMC studies between 1991-2009, there appears a favorable short-term effect of MMC on maintaining patency, preventing stenosis, and reducing adhesion formation (6) .
The present study tried to assess if a material that deeper covers the area of interest could improve the surgical outcome. The major results of this study are as follows:
1. Two applications of MMC present favorable patency rates of the frontal ostium compared with controls regardless the way of application.
2. A deeper application of MMC using an otowick seems to be a more effective way for the maintenance of frontal ostium patency.
Repetitious application of MMC have been proposed by many authors in experimental and clinical settings as a method for better results, a fact in agreement with our outcome (8, 9, 11) . One intraoperative MMC application seems to be not enough in endoscopic sinus surgery, as even a small bleeding in the surgical field can have a negative impact to local MMC concentration.
Except the number of applications, other important factors that can influence the results of MMC application include concentration and dosage, duration and method of application.
As the long-term safety of MMC application within the nasal cavity is not yet established, we have to avoid inadvertent contact of the drug with the adjacent nasal mucosa, applying MMC only onto the area of interest. The otowick provides a more precise and focused application of the drug covering deeper in a complete way the frontal ostium. The need for a deeper application was noticed in a recent case report by Gutierrez and Hopkins in which they applied MMC in a stenosed median frontal drainage through a nasopharyngeal tube trimmed with cottonoids (14) . A similar technique has been described in oesophageal strictures, however, is not very precise and standardized (15) . Our results
show that the use of a foamy material in the frontal sinus can be safe and effective providing an alternative tool for the local drug application.
The material used should be compatible for the injected solution in terms of equal expansion and drug distribution. MMC is diluted in an aqueous solution and otowick has been proven in a study by Clamp that presents significantly different rates of absorption into, and expansion when different drops were used (16) .
Specifically all aqueous ear drop preparations produced similar high rates of absorption and expansion, however, oil-based ear drop preparations failed to expand the wick and showed poor rates of absorption into it. The length of the otowick should be shortened to 6 mm. This is because the actual size of frontal sinus ostium as described by Lang et al. ranges from 1 to 6 mm (mean length of 3.08 mm) (10) .
In revision cases with osteoneogenesis around the frontal ostium, MMC had no favorable results. The presence of osteoneogenesis is considered as a factor of surgical failure (17) . It has been suggested that osteitic bone remnants act as an inflammatory nidus, inducing an inflammatory reaction which may contribute to frontal ostium stenosis.
The relatively small sample size of our study does not allow clear conclusions regarding the deeper MMC application into the frontal ostium although it's initial positive results.
It should be noted that none of the patients reported any studies systemic toxicity or adverse effects after sinonasal use of MMC, which is in agreement with a similar study (6) .
However, for higher concentrations and/or dosages the debate about concentration vs. safety remains to be addressed (18) . MMC is currently approved by the European Medicines Agency as an antineoplasmatic agent for certain types of cancer (e.g. gastric and pancreatic adenocarcinoma). Off-label, its use has been documented mainly in ophthalmology (pterygium, trabeculectomy) (19, 20) , plastic surgery (keloids) (21) and rhinology (dacrocystorhinostomy) (22) . Years of surgical experience in these fields have shown that the concentration used in our study for 5 minutes appears to be safe. None of the studies reported any adverse effects or systemic toxicity of topical MMC when applied for 5 minutes in a maximum concentration of 0.6 mg/mL (usual range in the literature 0.4-0.5 mg/ml) and a maximum dose of 1.5 mL.
Although no reports of local toxicity have been reported in rhinology, the ophthalmological literature has documented some serious, even vision-threatening complications. However, this resulted in patients taking MMC as eye drops for several days.
In addition, airway obstruction due to exudation reported in some cases of laryngotracheal stenosis and intraoperative MMC application, a fact mainly seen when a quite high concentration was used (10 mg/ml) (23) .
As many issues remain to be addressed regarding the safety of local MMC application, the described technique avoids an unnecessary contact of the drug with larger areas of nasal mucosa providing a more precise and deeper drug delivery.
Based on that and regardless the material that surgeons like, we conclude that deeper and precise MMC application may can affect the final outcome significantly.
